PE20171620A1 - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas - Google Patents
Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricasInfo
- Publication number
- PE20171620A1 PE20171620A1 PE2017002102A PE2017002102A PE20171620A1 PE 20171620 A1 PE20171620 A1 PE 20171620A1 PE 2017002102 A PE2017002102 A PE 2017002102A PE 2017002102 A PE2017002102 A PE 2017002102A PE 20171620 A1 PE20171620 A1 PE 20171620A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonimidoylpurinone
- prophylaxis
- treatment
- viric
- infections
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 102000002689 Toll-like receptor Human genes 0.000 abstract 2
- 108020000411 Toll-like receptor Proteins 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- WLAWDJREXFPHPH-VWLOTQADSA-N 6-amino-9-[(4-chlorophenyl)methyl]-2-(propylsulfonimidoyl)-7H-purin-8-one Chemical compound C(C1=CC=C(Cl)C=C1)N1C2=C(C(=NC([S@](=O)(=N)CCC)=N2)N)NC1=O WLAWDJREXFPHPH-VWLOTQADSA-N 0.000 abstract 1
- XFDVJIPIVPRMJX-UHFFFAOYSA-N 6-amino-9-benzyl-2-(ethylsulfonimidoyl)-7H-purin-8-one Chemical compound NC1=C2NC(N(C2=NC(=N1)S(=O)(=N)CC)CC1=CC=CC=C1)=O XFDVJIPIVPRMJX-UHFFFAOYSA-N 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015078507 | 2015-05-08 | ||
| CN2016078785 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171620A1 true PE20171620A1 (es) | 2017-11-02 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002102A PE20171620A1 (es) | 2015-05-08 | 2016-05-04 | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas |
Country Status (32)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ735648A (en) | 2015-05-08 | 2023-06-30 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| SG11201901633WA (en) | 2016-08-29 | 2019-03-28 | Hoffmann La Roche | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| WO2018050571A1 (en) * | 2016-09-13 | 2018-03-22 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| CA3091950A1 (en) * | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| CN119455003A (zh) * | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| CN114450280B (zh) | 2019-09-20 | 2025-02-25 | 先正达农作物保护股份公司 | 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132590A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| WO2024013205A1 (en) | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Phosphorylpurinone compounds for the treatment of cancer |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| JP2008540396A (ja) * | 2005-05-04 | 2008-11-20 | ファイザー・リミテッド | 癌およびｃ型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての２−アミド−６−アミノ−８−オキソプリン誘導体 |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| PE20120106A1 (es) | 2008-12-09 | 2012-02-20 | Gilead Sciences Inc | Moduladores de receptores tipo toll |
| WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| JP6349256B2 (ja) | 2011-11-09 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのプリン誘導体 |
| PL2978429T3 (pl) | 2013-03-29 | 2017-08-31 | Janssen Sciences Ireland Uc | Deazapurynony makrocykliczne do leczenia infekcji wirusowych |
| BR112017002811B1 (pt) | 2014-08-15 | 2022-09-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit |
| NZ735648A (en) * | 2015-05-08 | 2023-06-30 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| SG11201901633WA (en) * | 2016-08-29 | 2019-03-28 | Hoffmann La Roche | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
-
2016
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt active IP Right Grant
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh active
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171620A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas | |
| PE20160686A1 (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b | |
| MX2021005850A (es) | Heterociclos funcionalizados como agentes antivirales. | |
| CL2019000271A1 (es) | Inhibidores de polimerasa hcv. (divisional solicitud 201600493) | |
| PE20171648A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| CL2018003492A1 (es) | Hepatitis b agentes antivirales. | |
| PE20142148A1 (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
| BR112015021027A2 (pt) | compostos terapêuticos | |
| PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| PE20141558A1 (es) | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| PE20170679A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales | |
| CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
| AR094966A1 (es) | Composiciones farmacéuticas para el tratamiento de infecciones hcv | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| EA201591220A1 (ru) | Новые противовирусные агенты против инфекции вирусом гепатита в | |
| PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
| PE20140109A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina |